These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36266383)

  • 1. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
    Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
    Clinicoecon Outcomes Res; 2023; 15():739-752. PubMed ID: 37868649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.
    Bindra J; Chopra I; Niewoehner J; Panaccio M; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():349-358. PubMed ID: 33986603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
    Askanase AD; Furie RA
    Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
    Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
    J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.
    Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study.
    Alsuwayegh A; Almaghlouth IA; Almasaoud MA; Alzaid AS; Alsuhaibani AA; Almana LH; Alabdulkareem SM; Abudahesh JA; AlRuthia Y
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
    Goteti K; French J; Garcia R; Li Y; Casset-Semanaz F; Aydemir A; Townsend R; Mateo CV; Studham M; Guenther O; Kao A; Gastonguay M; Girard P; Benincosa L; Venkatakrishnan K
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):180-195. PubMed ID: 36350330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
    Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
    Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.
    Li X; Golubovsky J; Hui-Yuen J; Shah U; Olech E; Lomeo R; Singh V; Busch H; Strandberg MJ; Strandberg K; Horowitz L; Askanase A
    F1000Res; 2015; 4():1103. PubMed ID: 27158444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.